Holen Sie sich die Stockscreener-App
1.80
3.23%
-0.06
Handel nachbörslich:
1.78
-0.02
-1.11%
Schlusskurs vom Vortag:
$1.86
Offen:
$1.85
24-Stunden-Volumen:
583.97K
Relative Volume:
0.64
Marktkapitalisierung:
$291.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.7102
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
-3.23%
1M Leistung:
+11.11%
6M Leistung:
+168.74%
1J Leistung:
-88.46%
1-Tages-Spanne:
$1.74
$1.85
1-Wochen-Bereich:
$1.74
$2.02
52-Wochen-Spanne:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.80 | 301.22M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
What risks investors should watch in Neumora Therapeutics Inc. stockJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
Candlestick signals on Neumora Therapeutics Inc. stock todayMarket Risk Analysis & Scalable Portfolio Growth Methods - newser.com
Can a trend reversal in Neumora Therapeutics Inc. lead to recovery2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
What insider trading reveals about Neumora Therapeutics Inc. stockNew Guidance & Verified Momentum Watchlists - newser.com
Heatmap analysis for Neumora Therapeutics Inc. and competitorsTrade Ideas & Long Hold Capital Preservation Tips - newser.com
How moving averages guide Neumora Therapeutics Inc. tradingMarket Activity Summary & Free High Return Stock Watch Alerts - newser.com
Why Neumora Therapeutics Inc. stock is a must watch in 2025Quarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Can Neumora Therapeutics Inc. hit a new high this monthSell Signal & High Yield Stock Recommendations - newser.com
Using data models to predict Neumora Therapeutics Inc. stock movement2025 Dividend Review & Real-Time Volume Analysis Alerts - newser.com
Will Neumora Therapeutics Inc. see short term momentum2025 Valuation Update & Fast Moving Stock Trade Plans - newser.com
Neumora Therapeutics' (NMRA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Tools to monitor Neumora Therapeutics Inc. recovery probabilityJobs Report & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-09 06:47:56 - newser.com
Will Neumora Therapeutics Inc. stock attract more institutional investorsQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Visual analytics tools that track Neumora Therapeutics Inc. performanceTrade Entry Report & High Accuracy Trade Alerts - newser.com
Is Neumora Therapeutics Inc a good long term investmentVolume Weighted Average Price & Rapid Wealth Building Tips - earlytimes.in
Will breakout in Neumora Therapeutics Inc. lead to full recoveryWeekly Profit Report & AI Forecast Swing Trade Picks - newser.com
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Neumora Therapeutics Inc. recovery potential after sell offTrade Volume Report & Weekly Return Optimization Alerts - newser.com
Forecasting Neumora Therapeutics Inc. price range with options dataJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Is Neumora Therapeutics Inc. trending in predictive chart modelsGap Down & Risk Adjusted Buy and Sell Alerts - newser.com
Neumora Therapeutics to Host Virtual R&D Day Highlighting Innovative Therapeutics Pipeline on October 27, 2025 - Quiver Quantitative
Neumora Therapeutics to Host Virtual R&D Day on October 27 - Yahoo Finance
What analysts say about Neumora Therapeutics Inc stockMarket Sentiment Surveys & Start Your Free Trading Journey Today - earlytimes.in
What drives Neumora Therapeutics Inc stock priceEx-Dividend Date Alerts & Minimal Capital Growth Plans - earlytimes.in
Neumora Therapeutics Inc Stock Analysis and ForecastFederal Reserve Announcements & Free Proven Portfolio Growth Strategies - earlytimes.in
Neumora Therapeutics appoints Paul Berns as CEO - MSN
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neumora Therapeutics Inc-Aktie (NMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):